Insulin allergy and lipoatrophy in type 1 diabetic patients have been previously reported but the mechanisms are not well documented. Here, we report a case emphasizing the role of abnormal local immune reaction associated with cytokine hyper production. The patient is a 7-year-old boy with a familial history of common variable immunodeficiency. Eight months after the diagnosis of type 1 diabetes, he developed signs of insulin allergy expressed as continuously extensive and profound lipoatrophy contrasting with a well-preserved metabolic control. Specific insulin allergy was confirmed by skin prick tests that showed lymphoid activated cells in the subcutaneous tissue at the site of insulin injection. All therapies reported in the literature (antihistaminic, local steroid, change to lispro insulin, immunosuppressive treatment, subcutaneous insulin pump, peritoneal insulin infusion) were not efficient. It is suggested that familial disorders of immune cell functions with abnormal and excessive cytokine production might explain these adverse effects triggered by insulin with severe allergic reactions and lipoatrophy.

Keywords:
Insulin allergy, Lipoatrophy, Type 1 diabetes, Pump therapy
1.
Naf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I, Gomis R: Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002;25:634–635.
2.
Eapen SS, Connor EL, Gern JE: Insulin desensitization with insulin lispro and an insulin pump in a 5-year old child. Ann Allergy Asthma Immunol 2000;85:395–397.
3.
Kumar D: Lispro analogue for the treatment of generalized allergy to human insulin. Diabetes care 1997;20:1357–1359.
4.
Nagai Y, Mori T, Abe T, Nomura G: Immediate-type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient. Endocr J 2001;48:311–316.
5.
Reeves WG, Allen BR, Tattersall RB: Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J 1980;280:1500–1503.
6.
Takatsuki H, Ishii H, Yamauchi T, Nakashima N, Nagase S, Hisatomi A, Umeda F, Nawata H: A case of insulin allergy: the crystalline human insulin may mask its antigenicity. Diabetes Res Clin Pract 1991;12:137–139.
7.
Atlan-Gepner C, Bongrand P, Farnarier C, Xerri L, Choux R, Gauthier JF, Brue T, Vague P, Grob JJ, Vialettes B: Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care 1996;19:1283–1285.
8.
Jermendy G, Nadas J, Sapi Z: ‘Lipoblastoma-like’ lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes? Diabetologia 2000;43:955–956.
9.
Sola-Gazagnes A, Pecquet C, Radermecker R, Pietri L, Elgrably F, Slama G, Selam JL: Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care 2003;26:2961–2962.
10.
Griffin ME, Feder A, Tamborlane WV: Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care 2001;24:174.
11.
Ampudia-Blasco FJ, Hasbum B, Carmena R: A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications? Diabetes Care 2003;26:953–954.
12.
Reeves WG, Allen BR, Tattersall RB: Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J 1980;280:1500–1503.
13.
Petruschke T, Hauner H: Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endocrinol Metab 1993;76:742–747.
14.
Kudo M, Sugawara A, Uruno A, Takeuchi K, Ito S: Transcription suppression of peroxisome proliferator-activated receptor gamma2 gene expression by tumor necrosis factor alpha via an inhibition of CCAAT/enhancer-binding protein delta during the early stage of adipocyte differentiation. Endocrinology 2004;145:4948–4956.
15.
Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, Capeau J: Association between altered expression of adipogenic factor SREBP1 inlipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026–1031.
16.
Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, Rizzo LV: Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc 2004;76:707–726.
17.
Cambronero R, Sewell WA, North ME, Webster AD, Farrant J: Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J Immunol 2000;164:488–494.
18.
North ME, Webster AD, Farrant J: Primary defect in CD8+ lymphocytes in the antibody deficiency disease (common variable immunodeficiency): abnormalities in intracellular production of interferon-gamma (IFN-gamma) in CD28+ (‘cytotoxic’) and CD28- (‘suppressor’) CD8+ subsets. Clin Exp Immunol 1998;111:70–75.
19.
Barton JC, Bertoli LF, Acton RT: HLA-A and -B alleles and haplotypes in 240 index patients with common variable immunodeficiency and selective IgG subclass deficiency in central Alabama. BMC Med Genet 2003;12;4:3.
20.
Metin A, Tezcan I, Ozyurek H: IDDM in an adolescent patient with common variable immunodeficiency. Diabetes Care 1997;20:677–678.
21.
Conley ME, Park CL, Douglas SD: Childhood common variable immunodeficiency with autoimmune disease. J Pediatr 1986;108:915–922.
22.
Iglesias P, Ferreira A, Diez JJ: Common variable immunodeficiency in adult woman with IDDM. Diabetes Care 1998;21:1029.
23.
Johnston SL, Virgo PF, Unsworth DJ: Type 1 diabetes mellitus masking primary antibody deficiency. J Clin Pathol 2000;53:236–237.
24.
Arranz A, Andia V, Lopez-Guzman A: A case of lipoatrophy with lispro insulin without insulin pump therapy. Diabetes Care 2004;27:625–626.
25.
Airaghi L, Lorini M, Tedeschi A: The insulin analog as part: a safe alternative in insulin allergy. Diabetes Care 2001;24:2000.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.